Unlike the other checkpoints, PD‐L2 was not increased during acute COVID‐19, but a small group of patients showing very low PD‐L2 levels presented an increase at 1 year and persisted with structural and functional pulmonary alterations. Here, PDCD1LG2 is linked to COVID-19.